The call reflected a balance between strong performance in several product segments, particularly in medical devices and diabetes care, against challenges in the diagnostics segment and COVID testing sales decline. While growth in key areas is strong, the diagnostics challenges, especially in China, present significant headwinds.

Company Guidance -

Q3 2025

During Abbott's Second Quarter 2025 Earnings Conference Call, the company provided a detailed update on its financial guidance and performance. Abbott reported high single-digit sales growth, margin expansions exceeding 100 basis points in both gross and operating margins, and double-digit earnings per share growth. The sales growth, excluding COVID testing sales, was 7.5% in the second quarter and 8% for the first half of the year. Adjusted earnings per share for the second quarter were $1.26, reflecting an 11% increase compared to the prior year and a 16% sequential growth from the first quarter. The company also highlighted a 12% growth in Medical Devices, driven by strong performances in diabetes care and other sectors. Abbott's outlook for the rest of the year includes high single-digit growth and double-digit EPS growth despite facing headwinds, including a projected $700 million impact due to a decline in COVID testing sales and challenges in the Chinese market. Additionally, Abbott is preparing for a potential impact of tariffs estimated at $200 million. Looking forward, Abbott is optimistic about its product pipeline and the momentum heading into 2026, aiming for continued high single-digit growth and double-digit EPS growth.

Strong Sales Growth

Second quarter sales increased by 6.9% or 7.5% excluding COVID testing-related sales. Adjusted earnings per share of $1.26 increased 11% compared to the prior year.

Medical Devices Segment Success

Medical Devices sales grew 12%, driven by double-digit growth in diabetes care, heart failure, structural heart, electrophysiology, and cardiac rhythm management.

Diabetes Care Expansion

Sales of continuous glucose monitors were $1.9 billion in the quarter, growing by 19.5%. Abbott announced a collaboration with Epic for integrating Libre sensor data into health records.

EPD Sales Milestone

EPD sales grew nearly 8% in the quarter, surpassing $1 billion in quarterly sales for the first time in key markets including India and China.

Abbott Laboratories (ABT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ABT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 15, 2025	2025 (Q3)	1.30 / -	1.21	―	―	―
Jul 17, 2025	2025 (Q2)	1.26 / 1.26	1.14	10.53% (+0.12)
Apr 16, 2025	2025 (Q1)	1.07 / 1.09	0.98	11.22% (+0.11)
Jan 22, 2025	2024 (Q4)	1.34 / 1.34	1.19	12.61% (+0.15)
Oct 16, 2024	2024 (Q3)	1.20 / 1.21	1.14	6.14% (+0.07)
Jul 18, 2024	2024 (Q2)	1.10 / 1.14	1.08	5.56% (+0.06)
Apr 17, 2024	2024 (Q1)	0.95 / 0.98	1.03	-4.85% (-0.05)
Jan 24, 2024	2023 (Q4)	1.19 / 1.19	1.03	15.53% (+0.16)
Oct 18, 2023	2023 (Q3)	1.10 / 1.14	1.15	-0.87% (-0.01)
Jul 20, 2023	2023 (Q2)	1.05 / 1.08	1.43	-24.48% (-0.35)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ABT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 17, 2025	$131.74	$120.51	-8.52%
Apr 16, 2025	$125.66	$129.12	+2.75%
Jan 22, 2025	$115.73	$116.71	+0.85%
Oct 16, 2024	$114.40	$116.14	+1.52%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.